For rheumatoid arthritis or there will be new drugs!
Recently, the national class 1.1 new drug (FNS007 for injection) for rheumatoid arthritis has been approved to enter the phase I clinical phase. This drug acts on the initiation of rheumatoid arthritis, or will play a role in it. The role of the upper-stage disease treatment is a leap in the treatment principle of rheumatoid arthritis, which is of great significance.
According to the State Food and Drug Administration, recently, the national class 1.1 new drug (FNS007 for injection) for rheumatoid arthritis was approved for phase I clinical. Different from traditional RA treatment drugs, this drug acts on the upstream stage of rheumatoid arthritis, and it is expected to be the first rheumatoid arthritis treatment drug for the cause of the disease (antigen), which is of great significance.
The national class 1.1 new drug refers to a drug substance or preparation prepared by synthetic or semi-synthetic methods that is not marketed at home and abroad. It is reported that in recent years, the number of new types of 1.1 new drugs in China has gradually increased, mainly in the fields of cancer, digestive system and diabetes. The preliminary basic research of FNS007 for injection was completed by Peking University People’s Hospital. It was supported by the Rheumatoid Arthritis 973 Program and the National Eleventh Five-Year New Drug Creation Project. Professor Li Zhanguo was the project leader.
Rheumatoid arthritis is a systemic inflammatory autoimmune disease involving the surrounding joints. Data show that 75% of patients with rheumatoid arthritis can develop bone destruction within half a year after onset. Untreated rheumatoid arthritis patients have a disability rate of up to 70% in 3 years. More than 5 million patients with rheumatoid arthritis in China have a clinical response rate of less than 10%. Although the existing standard treatment can control the disease better in patients with good compliance, it can avoid joint damage or even visceral damage. However, due to the inability to cure the drug for a long time, the family and social burden of the patient is huge.
There are currently available anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, glucocorticoids, biological agents and botanicals for the treatment of rheumatoid arthritis. These drugs all play a role in the lymphocytes that inhibit the immune process, or in all aspects of the inflammatory response. Among them, biological agents have been marketed as new drugs with high vocalization, and are recommended for the improvement of rheumatoid arthritis patients with poor anti-rheumatic drugs. The mechanism of action is to inhibit or aggravate inflammation in the immune system. Specific ingredients to reduce inflammation and prevent joint damage.
The 1.1 new drug (FNS007 for injection), which is dedicated to the initiation of rheumatoid arthritis, from Phase I clinical to patient, must take several years, but for China’s large number of rheumatoid arthritis Patient, this breakthrough is very worthy of attention and expectation!